Pangaea Oncology (XMAD:PANG) LT-Debt-to-Total-Asset : 0.06 (As of Jun. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Pangaea Oncology LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Pangaea Oncology's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.06.

Pangaea Oncology's long-term debt to total assets ratio declined from Jun. 2023 (0.06) to Jun. 2024 (0.06). It may suggest that Pangaea Oncology is progressively becoming less dependent on debt to grow their business.

Pangaea Oncology LT-Debt-to-Total-Asset Historical Data

The historical data trend for Pangaea Oncology's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pangaea Oncology LT-Debt-to-Total-Asset Chart

Pangaea Oncology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.20

0.22

0.16

0.08

0.07

Pangaea Oncology Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.09	0.08	0.06	0.07	0.06

Pangaea Oncology LT-Debt-to-Total-Asset Calculation

Pangaea Oncology's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	1.864	/	28.834
	=	0.06

Pangaea Oncology's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	1.537	/	26.868
	=	0.06

Pangaea Oncology (XMAD:PANG) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Pangaea Oncology LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Pangaea Oncology's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Pangaea Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Pangaea Oncology SA (XMAD:PANG) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Calle Sabino Arana, 5-19, Barcelona, ESP, 08028

Website

http://www.panoncology.com

Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.

Pangaea Oncology Headlines

No Headlines